Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure. Intensive study has shown that ACE inhibitors significantly reduce mortality and morbidity and are well tolerated by the vast majority of patients with heart failure.1-4
The role of angiotension type 1 receptor blockers (ARBs) as an alternative to ACE inhibition or as an additional means of treatment in patients with heart failure has been evaluated in three recent trials: ELITE (Evaluation of Losartan in the Elderly), RESOLVD (Randomized Evaluation of Strategies for Left Ventricular Dysfunction), and ELITE II.5-7
References are listed at the end of the Data Alert.